Clarity Pharmaceuticals (ASX:CU6) will start a registrational phase 3 trial of copper-64-SARTATE in neuroendocrine tumors, following a successful end-of-phase meeting with the US Food and Drug Administration (FDA), according to a Thursday Australian bourse filing.

The company plans to recruit around 70 participants for the trial.

Clarity is also conducting recruitment for its registrational phase 3 positron emission tomography imaging trial of participants with high-risk prostate cancer prior to radical prostatectomy using copper-64-SAR-bisPSMA in the US and Australia, per the filing. It plans to recruit around 383 participants.

The trial will assess the diagnostic performance of copper-64-SAR-bisPSMA positron emission tomography in detecting prostate cancer within the pelvic lymph nodes, the filing said.

Clarity Pharmaceuticals' shares fell nearly 2% in recent trading on Thursday.